A risk factor for small left colon syndrome is having a mother with diabetes.Some symptoms that may indicate an underlying disease include:
Bowel movements that contain blood. Severe abdominal bloating. Peri-anal fistula
Absent anal wink reflex
Sacral dimple
Failure to thrive

Diagnosis
The Rome process suggests a diagnosis of constipation in children fewer than 4 years old when the child has 2 or more of the following complaints for at least 1 month. For children older than 4 years, there must be 2 of these complaints for at least 2 months. 2 or fewer bowel movements per week
Passing large bowel movements
On physical exam, a doctor may find large amounts of feces within the childs rectum. A child who is already toilet trained has at least 1 accident per week involving a bowel movement. Child demonstrates withholding behavior in which he or she actively tries not to pass a bowel movement. Hard stools
Pain with defecation.For children, the degree of constipation may be scored by the Leech or the Barr systems:

The Leech system assigns a score of 0 to 5 based on the amount of feces:0: no visible feces
1: scanty feces visible
2: mild fecal loading
3: moderate fecal loading
4: severe fecal loading
5: severe fecal loading with bowel dilatation
These score are assigned separately for the right colon, the left colon and the rectosigmoid colon, resulting in a maximum score of 15.
Large IHs can leave visible skin changes secondary to significant stretching of the skin or alteration of surface texture. When they interfere with vision, breathing, or threaten significant disfigurement (most notably facial lesions, and in particular, nose and lips), they are usually treated. Medical therapies are most effective when used during the period of most significant hemangioma growth, which corresponds to the first 5 months of life. Ulcerated hemangiomas, a subset of lesions requiring therapy, are usually treated by addressing wound care, pain, and hemangioma growth. Medication
Treatment options for IHs include medical therapies (systemic, intralesional, and topical), surgery, and laser therapy. Prior to 2008, the mainstay of therapy for problematic hemangiomas was oral corticosteroids, which are effective and remain an option for patients in whom beta-blocker therapy is contraindicated or poorly tolerated. Following the serendipitous observation that propranolol, a nonselective beta blocker, is well tolerated and effective for treatment of hemangiomas, the agent was studied in a large, randomized, controlled trial and was approved by the U.S. Food and Drug Administration for this indication in 2014. Oral propranolol is more effective than placebo, observation without intervention, or oral corticosteroids. Propranolol has subsequently become the first-line systemic medical therapy for treatment of these lesions.Since that time, topical timolol maleate in addition to oral propranalol has become a common therapy for infantile hemangiomas. According to a 2018 Cochrane review, both of these therapies have demonstrated beneficial effects in terms of clearance of hemangiomas without an increase in harms.